Opicinumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | LINGO-1 protein |
| Clinical data | |
| Other names | BIIB033 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6406H9896N1708O2012S44 |
| Molar mass | 144442.22 g·mol−1 |
Opicinumab (BIIB033) is a fully human monoclonal antibody designed for the treatment of multiple sclerosis, acute optic neuritis (AON), and other associated demyelinating diseases.[1] A biologic drug, it is designed to function as a LINGO-1 protein antagonist, known as "Anti-Lingo-1".[2]
Some Phase II clinical trials have been carried out, but preliminary results indicate that primary study endpoints were not met and that opicinumab exhibits unexpected dose-response relationships. Further studies were planned by the company, as opicinumab still was deemed to show potential for clinical efficacy in the treatment of MS.[1]
- ^ a b "Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis | Biogen Media". media.biogen.com. Retrieved 2016-11-21.
- ^ "Opicinumab". drugspider.com. Retrieved 2016-11-21.